BioCentury
ARTICLE | Company News

Pervasis, Shire deal

April 16, 2012 7:00 AM UTC

Shire will acquire Pervasis' vascular assets in a deal valued at up to $200 million, including an undisclosed upfront payment and milestones. The deal includes Vascugel, a biodegradable implant containing human endothelial cells in Phase II testing to prevent hemodialysis vascular access failure in patients with end-stage renal disease (ESRD). Shire said Vascugel will add to its regenerative medicine portfolio, which includes marketed diabetic foot ulcer therapy Dermagraft, gained last year through the acquisition of Advanced BioHealing Inc. (see BioCentury, July 4, 2011). ...